Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05011851
Recruitment Status : Not yet recruiting
First Posted : August 18, 2021
Last Update Posted : September 1, 2021
Sponsor:
Information provided by (Responsible Party):
Neuren Pharmaceuticals Limited

Brief Summary:
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome

Condition or disease Intervention/treatment Phase
Angelman Syndrome Drug: NNZ-2591 Phase 2

Detailed Description:
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Angelman syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment of orally administered NNZ-2591 oral solution (50 mg/mL) at weight-banded doses for a total of 13 weeks

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Estimated Study Start Date : October 1, 2021
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : September 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NNZ-2591
NNZ-2591 oral solution (50mg/mL) to be administered twice daily at a weight-banded dose for 13 weeks.
Drug: NNZ-2591
NNZ-2591 oral solution (50mg/mL) to be administered twice daily at a weight-banded dose for 13 weeks.
Other Name: Cyclo-L-Glycyl-L-2-Allylproline




Primary Outcome Measures :
  1. Safety and Tolerability [ Time Frame: 13 weeks ]
    To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.

  2. Pharmacokinetic - Measurement of Cmax [ Time Frame: 13 weeks ]
    Maximum observed concentration (Cmax) of NNZ-2591

  3. Pharmacokinetic - Measurement of AUC [ Time Frame: 13 weeks ]
    Area under the concentration-time curve of NNZ-2591

  4. Pharmacokinetic - Measurement of time to Cmax [ Time Frame: 13 weeks ]
    Time to Cmax of NNZ-2591

  5. Pharmacokinetic - Measurement of t1/2 [ Time Frame: 13 weeks ]
    Apparent terminal elimination half-life of NNZ-2591


Secondary Outcome Measures :
  1. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Angelman syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I)

  2. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Caregiver Impression of Improvement

  3. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Angelman syndrome-specific Clinical Global Impression Scales-Domain Improvement

  4. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Angelman syndrome-specific Clinical Global Impression Scale-Severity (CGI-S)-Overall and Domain

  5. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Angelman syndrome Clinician Domain Specific Rating Scale (AS-DSRS)

  6. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Caregiver Top 3 Concerns Likert Scale

  7. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by MacArthur-Bates Communicative Development Inventory (MB-CDI)

  8. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Observer-Reported Communication Ability (ORCA)

  9. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Aberrant Behavior Checklist-2 (ABC-2)

  10. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Child Sleep Habits Questionnaire (CSHQ)

  11. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Gastrointestinal Health Questionnaire (GIHQ)

  12. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Vineland Adaptive Behavior Scales-3, Interview version

  13. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Bayley Scales of Infant Development-4, Vineland Motor subscales

  14. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Caregiver Diaries

  15. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Quality of Life Inventory-Disability (QI-Disability)

  16. Exploratory efficacy measurement [ Time Frame: 13 weeks ]
    Assessed by Impact of Childhood Neurological Disability (ICND)-Overall quality of life rating



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinical diagnosis of AS with a documented disease-causing genetic etiology known to impact maternally derived UBE3A expression in brain.
  2. Males or females aged 3-17 years
  3. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 3 or greater at the Screening visit.
  4. Each subject must be able to swallow the study medication provided as a liquid solution.
  5. Caregiver(s) must have sufficient English language skills.

Exclusion Criteria:

  1. Mosaicism for disease-causing mutation.
  2. Clinically significant abnormalities in safety laboratory tests at Screening.
  3. Abnormal QTcF interval or prolongation at Screening.
  4. Any other clinically significant finding (as determined by the Investigator) on ECG at the Screening visit.
  5. Excluded concomitant treatments.
  6. Actively undergoing regression or loss of skills.
  7. Unstable seizure profile.
  8. Current clinically significant (as determined by the Investigator) cardiovascular, renal, hepatic, gastrointestinal, respiratory, endocrine disease, or clinically significant organ impairment.
  9. Current clinically significant (as determined by the Investigator) hypo or hyperthyroidism.
  10. Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes.
  11. Has planned surgery during the study.
  12. History of, or current, cerebrovascular disease or brain trauma.
  13. History of, or current catatonia or catatonia-like symptoms.
  14. History of, or current, malignancy.
  15. Current major or persistent depressive disorder (including bipolar depression).
  16. Significant, uncorrected visual or uncorrected hearing impairment.
  17. Allergy to strawberry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05011851


Contacts
Layout table for location contacts
Contact: Patrick Kim +61 2 9171 3267 Patrick.Kim@novotech-cro.com

Locations
Layout table for location information
Australia, New South Wales
Sydney Children's Hospital
Randwick, New South Wales, Australia, 2031
Contact: James Shaw         
Australia, Queensland
Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service
South Brisbane, Queensland, Australia, 4101
Contact: James Shaw         
Australia, Victoria
Austin Health
Heidelberg, Victoria, Australia, 3084
Contact: James Shaw         
Sponsors and Collaborators
Neuren Pharmaceuticals Limited
Investigators
Layout table for investigator information
Study Director: James Shaw Neuren Pharmaceuticals
Layout table for additonal information
Responsible Party: Neuren Pharmaceuticals Limited
ClinicalTrials.gov Identifier: NCT05011851    
Other Study ID Numbers: NEU-2591-AS-001
First Posted: August 18, 2021    Key Record Dates
Last Update Posted: September 1, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Neuren Pharmaceuticals Limited:
Angelman Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Angelman Syndrome
Syndrome
Disease
Pathologic Processes
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn